Divi's Labs signs agreement with global pharmaceutical company
Telangana: Divi's Laboratories has signed a long-term manufacturing and supply agreement with a global pharmaceutical company.
As part of the agreement, Divi’s will manufacture and supply advanced intermediates under commercially agreed terms. While the name of the partner and specific quantitative details remain undisclosed due to a confidentiality agreement, the company stated that it anticipates a meaningful contribution to revenue from this deal.
In a filing with the BSE, Divi’s noted, “The Agreement will benefit the customer with assured supply and the Company to expand its presence in custom synthesis.”
In addition, Divi’s announced plans for capacity addition at its manufacturing facilities with an estimated investment ranging between Rs 650 crore and Rs 700 crore, to be funded from internal accruals.
Read also: High level delegation from USFDA visits Divi's Labs Choutuppal facility
Established in the year 1990, Divi’s is a manufacturer of Active Pharmaceutical Ingredients offering products to over 95 countries. Divi’s manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma. The Company currently operates two manufacturing locations that are compliant with global regulatory standards and capable of producing annual requirements ranging from 10’s of kilos to 1000’s of tons. It complies with cGMP guidelines for both the manufacturing units, having been inspected numerous times by FDA, EU GMP , HEALTH CANADA, TGA, ANVISA , COFEPRIS, PMDA and MFDS health authorities.
Read also: CDSCO Panel Approves Sanofi's Protocol Amendment to study Tolebrutinib
